Diasorin SpA (WBO:DIAS) Beginning Cash Position: €-25 Mil (As of Dec. 2025)


WBO:DIAS Diasorin SpA WBO:DIAS
74 GF Score
Price €70.08
GF Value €90.10
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Diasorin SpA Beginning Cash Position?

Diasorin SpA WBO:DIAS +0.43% 74 Beginning Cash Position is €-25 Mil as of Dec. 2025. GuruFocus rates WBO:DIAS with a GF Score™ of 74/100 and a GF Value™ of €90.10 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Diasorin SpA's Beginning Cash Position for the quarter that ended in Dec. 2025 was €-25 Mil.

Diasorin SpA's quarterly Beginning Cash Position declined from Jun. 2025 (€345 Mil) to Sep. 2025 (€173 Mil) and declined from Sep. 2025 (€173 Mil) to Dec. 2025 (€-25 Mil).

Diasorin SpA's annual Beginning Cash Position increased from Dec. 2023 (€242 Mil) to Dec. 2024 (€280 Mil) and increased from Dec. 2024 (€280 Mil) to Dec. 2025 (€344 Mil).

Diasorin SpA Beginning Cash Position Related Terms

Diasorin SpA Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Diasorin SpA's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA Beginning Cash Position Chart

Diasorin SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 339.88 403.02 241.78 280.31 344.27

Diasorin SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 344.00 345.46 173.00 -25.27 166.00
WBO:DIAS
74GF Score
Diasorin SpA WBO:DIAS
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diasorin SpA Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €-25 Mil mean?
Diasorin SpA (WBO:DIAS) has a Beginning Cash Position of €-25 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Diasorin SpA and its competitors.
Is Diasorin SpA's Beginning Cash Position too high?
Diasorin SpA's current Beginning Cash Position is €-25 Mil. Overall, Diasorin SpA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Beginning Cash Position compare to TMO and DHR?
Diasorin SpA's Beginning Cash Position of €-25 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Diagnostics & Research company?
A good Beginning Cash Position depends on the Medical Diagnostics & Research industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Diasorin SpA and its competitors. Diasorin SpA's current Beginning Cash Position is €-25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (WBO:DIAS) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.10, compared to a current price of €70.08 — trading 22.2% below its estimated fair value. The current Beginning Cash Position is €-25 Mil. Diasorin SpA's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Diasorin SpA (WBO:DIAS), the current Beginning Cash Position is €-25 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diasorin SpA (WBO:DIAS) Overvalued in 2026?

Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued. The current stock price of €70.08 is trading 22.2% below its estimated GF Value™ of €90.10. GuruFocus considers Diasorin SpA to be Modestly Undervalued.

Key valuation signals for WBO:DIAS:

  • Beginning Cash Position: €-25 Mil
  • GF Value™: €90.10 vs. price of €70.08 (22.2% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the WBO:DIAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diasorin SpA Business Description

Address Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
74GF Score

Get the complete analysis for WBO:DIAS

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.08
Price
€90.10
GF Value